NZ334277A - 7'alpha'('xi'-aminoalkyl)estratrienes - Google Patents
7'alpha'('xi'-aminoalkyl)estratrienesInfo
- Publication number
- NZ334277A NZ334277A NZ334277A NZ33427797A NZ334277A NZ 334277 A NZ334277 A NZ 334277A NZ 334277 A NZ334277 A NZ 334277A NZ 33427797 A NZ33427797 A NZ 33427797A NZ 334277 A NZ334277 A NZ 334277A
- Authority
- NZ
- New Zealand
- Prior art keywords
- alpha
- hydrocarbyl
- aminoalkyl
- estratrienes
- halogen
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J53/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by condensation with a carbocyclic rings or by formation of an additional ring by means of a direct link between two ring carbon atoms, including carboxyclic rings fused to the cyclopenta(a)hydrophenanthrene skeleton are included in this class
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J53/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by condensation with a carbocyclic rings or by formation of an additional ring by means of a direct link between two ring carbon atoms, including carboxyclic rings fused to the cyclopenta(a)hydrophenanthrene skeleton are included in this class
- C07J53/002—Carbocyclic rings fused
- C07J53/004—3 membered carbocyclic rings
- C07J53/008—3 membered carbocyclic rings in position 15/16
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/32—Antioestrogens
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
- C07J41/0033—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005
- C07J41/0072—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring not covered by C07J41/0005 the A ring of the steroid being aromatic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J43/00—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
- C07J43/006—Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton spiro-condensed
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J53/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by condensation with a carbocyclic rings or by formation of an additional ring by means of a direct link between two ring carbon atoms, including carboxyclic rings fused to the cyclopenta(a)hydrophenanthrene skeleton are included in this class
- C07J53/002—Carbocyclic rings fused
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Steroid Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
7 alpha -(xi-Aminoalkyl)-oestratriene derivatives of formula (I) and their acid-addition salts wherein: SK = -(CH2)m-NA-CHB-CHD-(CH2)n-SOx-(CH2)3-E; A = H or 1-5C alkyl and B, D = H; or A+B = (CH2)p and D = H; or A+D = (CH2)q and B = H; E = optionally mono- to perfluorinated ethyl; R3 = H, 1-8C hydrocarbyl or COR3'; R3' = H, 1-8C hydrocarbyl or phenyl; R11 = H, halogen or ONO2; R14, R15a, R15b, R16a and R16b = H, or R14+R15a = a bond or a CH2 bridge, or R15b = Me and R15a = H, or R15a and R15b = Me, or R15b+R16b = a CH2 bridge, or R16a or R16b = halogen, or R16a+R16b = methylidene; and the remaining substituents from R14, R15a, R15b, R16a and R16b = H; R17' = H, alkyl, 2-5C alkenyl, 2-5C alkynyl or CF3, or R17'+R14 = CH2CH2 when R17' is in the alpha position; R17" = H or COR17"'; R17"' = H or hydrocarbyl; m = 4-6, n, x = 0-2, p = 2-5, q = 2-4; provided that, if A+B do not form (CH2)p or A+D do not form (CH2)q then R11, R14, R15a, R15a, R16a and R16b are not all H.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
NZ507075A NZ507075A (en) | 1996-08-20 | 1997-08-20 | Intermediate compounds for preparing 7a-(-aminoalkyl)-estratrienes |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19635525A DE19635525A1 (en) | 1996-08-20 | 1996-08-20 | New 7-alpha-(xi-aminoalkyl)- oestratriene derivatives |
PCT/EP1997/004517 WO1998007740A1 (en) | 1996-08-20 | 1997-08-20 | 7α-(κ-AMINOALKYL)ESTRATRIENES, PROCESS FOR PREPARING THE SAME, PHARMACEUTICAL PREPARATIONS CONTAINING SAID 7α-(κ-AMINOALKYL)ESTRATRIENES AND THEIR USE FOR PREPARING MEDICAMENTS |
Publications (1)
Publication Number | Publication Date |
---|---|
NZ334277A true NZ334277A (en) | 2000-10-27 |
Family
ID=7804367
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NZ334277A NZ334277A (en) | 1996-08-20 | 1997-08-20 | 7'alpha'('xi'-aminoalkyl)estratrienes |
Country Status (29)
Country | Link |
---|---|
EP (1) | EP0920441B1 (en) |
JP (1) | JP2001503024A (en) |
KR (1) | KR20000068261A (en) |
CN (1) | CN1231670A (en) |
AR (1) | AR009278A1 (en) |
AT (1) | ATE231882T1 (en) |
AU (1) | AU728843B2 (en) |
BG (1) | BG62972B1 (en) |
BR (1) | BR9711328A (en) |
CA (1) | CA2263708A1 (en) |
CZ (1) | CZ57999A3 (en) |
DE (2) | DE19635525A1 (en) |
DK (1) | DK0920441T3 (en) |
EA (1) | EA001577B1 (en) |
EE (1) | EE04021B1 (en) |
ES (1) | ES2191857T3 (en) |
HU (1) | HUP9903106A3 (en) |
IL (1) | IL128601A (en) |
IS (1) | IS4976A (en) |
NO (1) | NO315655B1 (en) |
NZ (1) | NZ334277A (en) |
PL (1) | PL186309B1 (en) |
PT (1) | PT920441E (en) |
SK (1) | SK18899A3 (en) |
TR (1) | TR199900432T2 (en) |
TW (1) | TW552267B (en) |
UA (1) | UA50792C2 (en) |
WO (1) | WO1998007740A1 (en) |
ZA (1) | ZA977482B (en) |
Families Citing this family (53)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PE20000129A1 (en) * | 1997-12-23 | 2000-03-11 | Schering Ag | 11 BETA-HALOGEN-STRATRIENS SUBSTITUTED IN 7 ALPHA, AS WELL AS THE PROCEDURE TO PREPARE PHARMACEUTICAL PREPARATIONS CONTAINING SUCH 11 BETA-HALOGEN-STRATRENS SUBSTITUTED IN 7 ALPHA |
US6054446A (en) | 1997-12-24 | 2000-04-25 | Sri International | Anti-estrogenic steroids, and associated pharmaceutical compositions and methods of use |
US6503896B1 (en) | 1997-12-24 | 2003-01-07 | Sri International | Anti-estrogenic steroids, and associated pharmaceutical compositions and methods of use |
US6548491B2 (en) | 1997-12-24 | 2003-04-15 | Sri International | Anti-estrogenic steroids, and associated pharmaceutical compositions and methods of use |
DE19807791A1 (en) | 1998-02-19 | 1999-08-26 | Schering Ag | Combination preparation of estrogen with 7-aminoalkyl-estratriene antiestrogen, useful in hormone replacement therapy, e.g. for treatment osteoporosis, Alzheimer's disease and hot flushes |
DE19833786A1 (en) * | 1998-07-18 | 2000-01-20 | Schering Ag | New diphenyl-benzocycloheptene derivatives, are tissue-selective estrogens and antiestrogens useful e.g. for treating osteoporosis or hormone-dependent tumors or in hormone replacement therapy |
DE19842123C1 (en) * | 1998-09-05 | 2000-07-13 | Schering Ag | 11beta-fluoro-7alpha- (14,14,15,15,15-pentafluoro-6-methyl-10-thia-6-azapentadecyl) estra-1,3,5 (10) - triene-3,17beta-diol as crystalline solvate |
DE19906159A1 (en) * | 1999-02-09 | 2000-08-10 | Schering Ag | 16-hydroxyestratrienes as selectively active estrogens |
WO2001012622A1 (en) * | 1999-08-18 | 2001-02-22 | Schering Aktiengesellschaft | Piperidine and pyrrolidine derivatives displaying neuronal activity |
GB0000313D0 (en) * | 2000-01-10 | 2000-03-01 | Astrazeneca Uk Ltd | Formulation |
DE10019171A1 (en) * | 2000-04-07 | 2001-10-18 | Schering Ag | Compositions for use as penetration enhancers in transdermal formulations for highly lipophilic active ingredients |
AU2006202187B2 (en) * | 2001-11-27 | 2008-11-06 | Bayer Schering Pharma Aktiengesellschaft | 17alpah-alkyl-17beta-oxy-estratrienes and intermediate products for their production, uses thereof and pharmaceutical preparations |
DE10159217A1 (en) * | 2001-11-27 | 2003-06-05 | Schering Ag | 17alpha-alkyl-17ß-oxy-estratrienes and intermediates for their preparation, use of 17alpha-alkyl-17ß-oxy-estratriene for the preparation of medicaments and pharmaceutical preparations |
US20040242551A1 (en) * | 2003-05-28 | 2004-12-02 | Schering Ag | Composition comprising antiprogestins and pure antiestrogens for prophylaxis and treatment of hormone-dependent diseases |
TW200617019A (en) | 2004-07-27 | 2006-06-01 | Sicor Inc | A process for the preparation of 7α-alkylated 19-norsteroids |
WO2007060839A1 (en) | 2005-11-22 | 2007-05-31 | Sumitomo Chemical Company, Limited | Organic sulfur compounds and use thereof as arthropodicides |
DE102007023614A1 (en) | 2007-05-21 | 2008-11-27 | Bayer Schering Pharma Aktiengesellschaft | New amide compounds used for treatment of gynecological diseases e.g. endometriosis, for female fertility control and female hormone replacement therapy, has general formula |
DE102007049630A1 (en) | 2007-10-11 | 2009-10-29 | Bayer Schering Pharma Aktiengesellschaft | New amide compounds used for therapy and/or prophylaxis of gynecological diseases e.g. endometriosis, for female fertility control and female hormone replacement therapy |
TW200904329A (en) | 2007-05-18 | 2009-02-01 | Sumitomo Chemical Co | Organic sulfur compound and its use for controlling harmful arthropod |
JP2009001551A (en) | 2007-05-18 | 2009-01-08 | Sumitomo Chemical Co Ltd | Organic sulfur compound and its use for controlling harmful arthropod |
JP5298631B2 (en) | 2007-05-18 | 2013-09-25 | 住友化学株式会社 | Organic sulfur compounds and their use for controlling harmful arthropods |
DE102007032800A1 (en) | 2007-07-10 | 2009-01-15 | Bayer Schering Pharma Aktiengesellschaft | Nonsteroidal progesterone receptor modulators |
NZ591955A (en) | 2007-10-16 | 2011-10-28 | Repros Therapeutics Inc | Trans-clomiphene for diabetes mellitus type 2 |
DE102007058747A1 (en) | 2007-12-05 | 2009-06-10 | Bayer Schering Pharma Aktiengesellschaft | Nonsteroidal progesterone receptor modulators |
EP2070941A1 (en) | 2007-12-14 | 2009-06-17 | Bayer Schering Pharma Aktiengesellschaft | Stereoselective synthesis of selective estrogen receptor down-regulators |
EP2070909A1 (en) | 2007-12-15 | 2009-06-17 | Bayer Schering Pharma AG | Non-steroidal progesterone receptor modulators |
DE102008057230A1 (en) * | 2008-11-11 | 2010-05-12 | Bayer Schering Pharma Aktiengesellschaft | Synergistic pharmaceutical combination with an estrogen receptor antagonist and a progestin |
JP5212350B2 (en) * | 2008-12-24 | 2013-06-19 | 住友化学株式会社 | Halogen-containing organic sulfur compounds and uses thereof |
EP2258375A1 (en) | 2009-06-04 | 2010-12-08 | Bayer Schering Pharma Aktiengesellschaft | 17B-alkyl-17alpha-oxy-estratrienes |
DE102009034362A1 (en) | 2009-07-20 | 2011-01-27 | Bayer Schering Pharma Aktiengesellschaft | 17-Hydroxy-17-pentafluoroethyl-estra-4,9 (10) -diene-11-aryl derivatives, process for their preparation and their use for the treatment of diseases |
DE102009034368A1 (en) | 2009-07-20 | 2011-01-27 | Bayer Schering Pharma Aktiengesellschaft | 17-Hydroxy-17-pentafluoroethyl-estra-4,9 (10) -diene-11-acyloxyalkylenephenyl derivatives, process for their preparation and their use for the treatment of diseases |
DE102009034367A1 (en) | 2009-07-20 | 2011-01-27 | Bayer Schering Pharma Aktiengesellschaft | 17-Hydroxy-17-pentafluoroethyl-estra-4,9 (10) -diene-11-benzylidene derivatives, process for their preparation and their use for the treatment of diseases |
DE102009034366A1 (en) | 2009-07-20 | 2011-01-27 | Bayer Schering Pharma Aktiengesellschaft | 17-Hydroxy-17-pentafluoroethyl-estra-4,9 (10) -diene-11-methyleneoxyalkylene aryl derivatives, process for their preparation and their use for the treatment of diseases |
DE102009034526A1 (en) | 2009-07-21 | 2011-02-10 | Bayer Schering Pharma Aktiengesellschaft | 17-Hydroxy-17-pentafluoroethyl-estra-4,9 (10) -diene-11-ethynylphenyl derivatives, process for their preparation and their use for the treatment of diseases |
DE102009034525A1 (en) | 2009-07-21 | 2011-01-27 | Bayer Schering Pharma Aktiengesellschaft | 17-Hydroxy-17-pentafluoroethyl-estra-4,9 (10) -diene-11-aryl derivatives, process for their preparation and their use for the treatment of diseases |
WO2011092127A1 (en) | 2010-01-26 | 2011-08-04 | Bayer Schering Pharma Aktiengesellschaft | 14,17-bridged estratriene derivatives comprising heterocyclic bioisosteres for the phenolic a-ring |
DE102010007722A1 (en) | 2010-02-10 | 2011-08-11 | Bayer Schering Pharma Aktiengesellschaft, 13353 | Progesterone receptor antagonist |
DE102010007719A1 (en) | 2010-02-10 | 2011-08-11 | Bayer Schering Pharma Aktiengesellschaft, 13353 | Progesterone receptor antagonist |
KR20160088947A (en) | 2010-06-16 | 2016-07-26 | 앙도르쉐르슈 인코포레이티드 | Methods of treating or preventing estrogen-related diseases |
DE102010030538A1 (en) | 2010-06-25 | 2011-12-29 | Bayer Schering Pharma Aktiengesellschaft | 6,7-Dihydro-5H-benzo [7] annulene derivatives, process for their preparation, pharmaceutical preparations containing them and their use for the preparation of medicaments |
DE102011004899A1 (en) | 2011-03-01 | 2012-09-06 | Bayer Pharma Aktiengesellschaft | New 17-hydroxy-17-pentafluoroethyl-estra-4,9(10)-dien-11-aryl-derivatives are progesterone receptor antagonists useful to treat and prevent e.g. uterine fibroids, endometriosis, heavy menstrual bleeding and meningioma |
DE102011087987A1 (en) | 2011-12-08 | 2013-06-13 | Bayer Intellectual Property Gmbh | 6,7-Dihydro-5H-benzo [7] annulene derivatives, process for their preparation, pharmaceutical preparations containing them and their use for the preparation of medicaments |
WO2013130832A1 (en) | 2012-02-29 | 2013-09-06 | Repros Therapeutics Inc. | Combination therapy for treating androgen deficiency |
SI3461834T1 (en) | 2013-03-13 | 2021-11-30 | Sage Therapeutics, Inc. | Neuroactive steroids |
CN105120873A (en) | 2013-04-11 | 2015-12-02 | 拜耳制药股份公司 | Progesterone receptor antagonist dosage form |
JP6356218B2 (en) * | 2013-04-18 | 2018-07-11 | シーアン リーバン ファーマシューティカル テクノロジー シーオー., エルティーディー.Xi’An Libang Pharmaceutical Technology Co., Ltd. | Of 7-α- [9- (4,4,5,5,5-pentafluoropentylsulfinyl) nonyl] -estradi-1,3,5 (10) -triene-3,17β-diol having antitumor activity Ester derivatives and methods for their preparation |
US11633382B2 (en) | 2015-11-10 | 2023-04-25 | Paracrine Therapeutics Ab | Treatment of ER-negative breast cancer with an PDGF-CC inhibitor and anti-estrogen |
PL3436022T3 (en) | 2016-04-01 | 2022-08-08 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
US10752653B2 (en) | 2016-05-06 | 2020-08-25 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
EP3919502A1 (en) | 2016-07-07 | 2021-12-08 | Sage Therapeutics, Inc. | 11-substituted 24-hydroxysterols for use in the treatment of nmda related conditions |
MA46351A (en) | 2016-09-30 | 2021-06-02 | Sage Therapeutics Inc | C7 SUBSTITUTED OXYSTEROLS AND PROCESSES AS NMDA MODULATORS |
WO2018075698A1 (en) | 2016-10-18 | 2018-04-26 | Sage Therapeutics, Inc. | Oxysterols and methods of use thereof |
CN115505019B (en) * | 2022-11-07 | 2024-01-26 | 南宁师范大学 | 7-amide substituted estrogenic compounds, and preparation method and application thereof |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8327256D0 (en) * | 1983-10-12 | 1983-11-16 | Ici Plc | Steroid derivatives |
HU208150B (en) * | 1988-10-31 | 1993-08-30 | Endorecherche Inc | Process for producing new estrogen derivatives having steroid hormone inhibitor activity and pharmaceutical compositions comprising such derivatives |
DE3925507A1 (en) * | 1989-07-28 | 1991-01-31 | Schering Ag | 14,17 (ALPHA) ETHENO AND ETHANOESTRATRIA, METHOD FOR PRODUCING THESE COMPOUNDS, AND THEIR USE FOR PRODUCING MEDICINAL PRODUCTS |
DE4218743C2 (en) * | 1992-06-04 | 2001-10-25 | Schering Ag | Process for the preparation of C (7) -substituted Estra-1,3,5 (10) -trienes and new starting products for this process |
-
1996
- 1996-08-20 DE DE19635525A patent/DE19635525A1/en not_active Withdrawn
-
1997
- 1997-08-20 KR KR1019997001396A patent/KR20000068261A/en not_active Application Discontinuation
- 1997-08-20 EA EA199900210A patent/EA001577B1/en not_active IP Right Cessation
- 1997-08-20 TR TR1999/00432T patent/TR199900432T2/en unknown
- 1997-08-20 AT AT97943814T patent/ATE231882T1/en not_active IP Right Cessation
- 1997-08-20 CA CA002263708A patent/CA2263708A1/en not_active Abandoned
- 1997-08-20 PT PT97943814T patent/PT920441E/en unknown
- 1997-08-20 NZ NZ334277A patent/NZ334277A/en unknown
- 1997-08-20 DE DE59709239T patent/DE59709239D1/en not_active Expired - Fee Related
- 1997-08-20 HU HU9903106A patent/HUP9903106A3/en unknown
- 1997-08-20 DK DK97943814T patent/DK0920441T3/en active
- 1997-08-20 TW TW086111927A patent/TW552267B/en active
- 1997-08-20 BR BR9711328A patent/BR9711328A/en unknown
- 1997-08-20 PL PL97331863A patent/PL186309B1/en not_active IP Right Cessation
- 1997-08-20 IL IL12860197A patent/IL128601A/en not_active IP Right Cessation
- 1997-08-20 EP EP97943814A patent/EP0920441B1/en not_active Expired - Lifetime
- 1997-08-20 JP JP10510412A patent/JP2001503024A/en not_active Ceased
- 1997-08-20 CZ CZ99579A patent/CZ57999A3/en unknown
- 1997-08-20 AU AU45520/97A patent/AU728843B2/en not_active Ceased
- 1997-08-20 WO PCT/EP1997/004517 patent/WO1998007740A1/en not_active Application Discontinuation
- 1997-08-20 CN CN97198245A patent/CN1231670A/en active Pending
- 1997-08-20 SK SK188-99A patent/SK18899A3/en unknown
- 1997-08-20 ES ES97943814T patent/ES2191857T3/en not_active Expired - Lifetime
- 1997-08-20 AR ARP970103779A patent/AR009278A1/en not_active Application Discontinuation
- 1997-08-20 UA UA99031552A patent/UA50792C2/en unknown
- 1997-08-20 EE EEP199900075A patent/EE04021B1/en not_active IP Right Cessation
- 1997-08-20 ZA ZA9707482A patent/ZA977482B/en unknown
-
1999
- 1999-02-11 IS IS4976A patent/IS4976A/en unknown
- 1999-02-16 BG BG103185A patent/BG62972B1/en unknown
- 1999-02-19 NO NO19990793A patent/NO315655B1/en not_active IP Right Cessation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NZ334277A (en) | 7'alpha'('xi'-aminoalkyl)estratrienes | |
WO2001007433A3 (en) | Quinoline derivatives and their use as antibacterial agents | |
MXPA01011199A (en) | Free flowing polyester molding composition. | |
MY122649A (en) | Multiple phase compositions. | |
MY129000A (en) | INHIBITORS OF a4 MEDIATED CELL ADHESION | |
CA2263983A1 (en) | Cyclic amine derivatives for inhibiting blood platelet aggregation | |
ATE236185T1 (en) | MACROCYCLIC DERIVATIVES OF ERYTHROMYCIN A AND B WITH 13 RING ATOMS | |
CA2425876A1 (en) | Piperidine derivatives as antagonists of tachykinins | |
GB0002666D0 (en) | Blockade of voltage dependent sodium channels | |
AU9092501A (en) | Compositions and methods for inhibition of hiv-1 infection | |
NZ518296A (en) | N-phenyl-1,2-dihydro-2-oxo-quinoline-3-carboxamide derivatives and their use in the treatment of breast and prostatic cancer | |
IL139967A (en) | Beta-alanine derivatives and pharmaceutical compositions containing the same | |
HK1064936A1 (en) | Use of polyclonal anti-hiv goat serum as a therapeutic agent | |
AU694309B2 (en) | Azepinone compounds useful in the inhibition of ACE and NEP | |
IL153836A0 (en) | Novel form of (r)-n-[5-methyl-8-(4-methylpiperazin-1-yl)-1,2,3,4-tetrahydro-2-naphthyl]-4-morpholinobenzamide | |
BG102753A (en) | New taxoids, their preparation and phamaceutical compositions containing them | |
BG105651A (en) | Vitronectin receptor antagonist | |
HUP0204111A3 (en) | Novel process for the preparation of alpha-(2,4-disulfophenyl)-n-tert-butylnitrone and pharmaceutically acceptable salts thereof | |
WO2002024727A3 (en) | New inhibitors of iapp fibril formation and uses thereof | |
WO2001064685A3 (en) | Thienopyridine derivatives and their use as anti-inflammatory agents | |
FR2742155B1 (en) | USE OF HETEROAROMATIC AND TRICYCLIC DERIVATIVES OF 1,4-DIHYDRO-1,4-DIOXONAPHTALENE, NOVEL COMPOUNDS OBTAINED AND THEIR APPLICATION IN THERAPEUTICS | |
AU5465198A (en) | Hetero-biaryl-pyridoquinazolinone derivatives as anti-cancer agents | |
WO1996020209A3 (en) | 14α,17α-C2-BRIDGED 19-NOR-PROGESTERONE DERIVATIVES | |
SI1250320T1 (en) | Novel process for the preparation of alpha-(2,4-disulfophenyl)-n-tert-butylnitrone and pharmaceutically acceptable salts thereof | |
WO2001055088A3 (en) | Novel monomers with quaternary amino groups, method for making same, and novel (co)polymers obtained from said novel monomers |